In a patient on clonazepam 1 mg daily, hydrocodone/acetaminophen 7.5 mg twice daily, and buspirone 15 mg at bedtime who remains aggressive, what additional medication can be added?

Critical Safety Concern: Reassess Current Regimen Before Adding Medications

You should NOT add another medication to this regimen—instead, you must immediately address the dangerous combination of clonazepam and hydrocodone/acetaminophen, which significantly increases respiratory depression and mortality risk. 1

Immediate Actions Required

1. Address the Benzodiazepine-Opioid Combination

The current regimen contains a black box warning combination: clonazepam (benzodiazepine) with Norco (opioid). The FDA explicitly warns that concomitant use of benzodiazepines and opioids increases risk of respiratory depression, sedation, and death because they act at different CNS receptor sites (GABA-A and mu receptors, respectively) 1.

Before adding any medication for aggression:

• Limit the dosage and duration of this combination
• Consider tapering one agent (preferably the benzodiazepine given chronic use risks)
• If both must continue, closely monitor for respiratory depression

2. Establish the Underlying Diagnosis

Aggression is a symptom, not a diagnosis. You must identify what is driving the aggressive behavior:

Key diagnostic considerations:

• Psychotic disorder (schizophrenia, schizoaffective disorder)
• Bipolar disorder (manic or mixed episode)
• Major depressive disorder with agitation
• Personality disorder
• Cognitive impairment/dementia
• Substance use (particularly given opioid prescription)
• Organic causes (hypothyroidism, head injury, medical illness)

3. Medication Options Based on Diagnosis

If Psychotic Disorder or Bipolar Disorder:

Add a second-generation antipsychotic as first-line treatment:

• Risperidone 1-2 mg daily (titrate to 4-6 mg)
• Olanzapine 5-10 mg daily (titrate to 10-20 mg)
• Aripiprazole 10-15 mg daily (may reduce negative symptoms if combined with another antipsychotic) 2

For treatment-resistant aggression after adequate trial of first antipsychotic, clozapine is the gold standard for controlling aggression across multiple psychiatric diagnoses (bipolar disorder, intellectual disability, cognitive impairment, personality disorders) 3. Clozapine was effective in 504 patients with treatment-refractory aggressive behavior at doses averaging 350 mg/day for manic patients 3.

If Non-Psychotic Aggression:

Propranolol 40-80 mg BID (titrate up to 320-640 mg/day in divided doses):

• Demonstrated >50% reduction in aggressive behavior in 35% of chronically aggressive hospitalized patients 4
• Monitor for bradycardia, hypotension, bronchospasm
• Contraindicated in asthma, heart block, severe bradycardia

Valproic acid 250-500 mg BID (titrate to therapeutic levels 50-125 mcg/mL):

• Effective for aggression related to mood instability, impulse control disorders
• Monitor liver function and platelets

4. Critical Pitfalls to Avoid

Do not simply add more sedating medications to this already dangerous polypharmacy:

• The buspirone 15 mg QHS is subtherapeutic (typical dosing is 15-30 mg BID-TID for anxiety)
• Adding another benzodiazepine would worsen respiratory depression risk
• The current regimen may be causing paradoxical agitation, particularly in elderly patients 1

Paradoxical reactions (increased aggression, agitation) occur more commonly with benzodiazepines in children and elderly 1. Consider whether clonazepam is contributing to the problem.

Recommended Algorithm

1. Taper and discontinue clonazepam (gradually to avoid withdrawal seizures) OR discontinue Norco if pain can be managed otherwise
2. Optimize buspirone to therapeutic dosing (15 mg BID or TID) if anxiety is the primary driver
3. Add antipsychotic based on underlying diagnosis:
   • Start risperidone 1 mg BID or olanzapine 5 mg QHS
   • Titrate over 1-2 weeks based on response
4. If inadequate response after 4 weeks at therapeutic dose, consider clozapine (requires hematologic monitoring) 3
5. If non-psychotic aggression, trial propranolol 40 mg BID, titrate to effect 4

The priority is reducing mortality risk from the current benzodiazepine-opioid combination while addressing the root cause of aggression with appropriate psychiatric medication.